VAGUS NERVE STIMULATORS MARKET ANALYSIS
Vagus Nerve Stimulators Market by Product Type (Implantable Devices, and External Devices), by Application (Epilepsy, Depression, Cluster Headache & Migraine, and Others), by Distribution Channel (Hospital, Specialty Pharmacy, and Others), by Distribution Channel (Hospital, Retail Pharmacy, and Online Pharmacy) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
Vagus nerve stimulation (VNS) is a U.S. Food and Drug Administration (FDA) approved therapy, which involves stimulation of vagus nerve with the help of stimulator that provides electric impulses to vagus nerve. Vagus nerve stimulator is widely used in the treatment of epilepsy, depression, cluster headache, migraine, asthma, bronchoconstriction, exercise-induced bronchospasm, chronic obstructive pulmonary disease (COPD), gastric motility disorder, and irritable bowel syndrome. Currently, there are two types of vagus nerve stimulator present in the market- implantable vagus nerve device and external vagus nerve device. Implantable devices are implanted inside the body surgically. However, the external devices are nob-invasive and are used outside the body
Market Dynamics
High prevalence of depression epilepsy and migraine in key regions is expected to drastically rise demand for vagus nerve stimulators for its treatment. For instance, according to the data published by the Centers for Disease Control and Prevention in 2015, around 3 million U.S. adults and 470,000 children had active epilepsy (under treatment or with recent seizures). The number of adults with active epilepsy increased from 2.3 million in 2010 to 3 million in 2015.
According to the data published by National Institute of Mental Health in 2016, an estimated 16.2 million adults in the U.S. had at least one major depressive episode. This number represented 6.7% of all U.S. adults. According to the same source the prevalence of major depressive episode was higher among adult females (8.5%) compared to males (4.8%) and the prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%).
Approval and launch of novel products in market is also expected to support the vagus nerve stimulators market growth over the forecast period. For instance, in June 2017, electroCore, Inc. received the U.S. Food and Drug Administration (FDA) 510(k) clearance to market a newer version of gammaCore (non-invasive vagus nerve stimulator) – the gammaCore-S – for acute treatment of pain associated with episodic cluster headache (eCH) in adult patients.
Furthermore, in February 2019, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its national coverage determination (NCD) for the LivaNova Plc.’s vagus nerve stimulation therapy (VNS Therapy) System for treatment-resistant depression (TRD). Such favorable reimbursements for VNS devices for depression treatment is also expected to increase its adoption and drive vagus nerve stimulators market growth
Key features of the study:
- This report provides in-depth analysis of global vagus nerve stimulators market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
- It profiles leading players in the global vagus nerve stimulators market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include electroCore, Inc., LivaNova, PLC, SetPoint Medical Corporation, MicroTransponder, Inc., Beijing PINS Medical Co., Ltd., Parasym Ltd., Nervana, LLC., and tVNS Technologies GmbH
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global vagus nerve stimulators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the vagus nerve stimulators market
Detailed Segmentation:
- Global Vagus Nerve Stimulators Market, By Product Type:
- Implantable Devices
- External Devices
- Global Vagus Nerve Stimulators Market, By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- Global Vagus Nerve Stimulators market, By Distribution Channel:
- Hospital
- Specialty Pharmacy
- Others
- Global Vagus Nerve Stimulators Market, By Geography:
- North America
- By Product Type :
- Implantable Devices
- External Devices
- By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- By Distribution Channel
- Hospital
- Specialty Pharmacy
- Others
- By Country:
- U.S.
- Canada
- Europe
- By Product Type :
- Implantable Devices
- External Devices
- By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- By Distribution Channel
- Hospital
- Specialty Pharmacy
- Others
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type :
- Implantable Devices
- External Devices
- By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- By Distribution Channel
- Hospital
- Specialty Pharmacy
- Others
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Product Type :
- Implantable Devices
- External Devices
- By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- By Distribution Channel
- Hospital
- Specialty Pharmacy
- Others
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- By Product Type :
- Implantable Devices
- External Devices
- By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- By Distribution Channel
- Hospital
- Specialty Pharmacy
- Others
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type :
- Implantable Devices
- External Devices
- By Application:
- Epilepsy
- Depression
- Cluster Headache & Migraine
- Others
- By Distribution Channel
- Hospital
- Specialty Pharmacy
- Others
- By Country:
- Central Africa
- South Africa
- North Africa
- Company Profiles
- electroCore, Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- LivaNova, PLC
- SetPoint Medical Corporation
- MicroTransponder, Inc.
- Beijing PINS Medical Co., Ltd.
- Parasym Ltd.
- Nervana, LLC.
- tVNS Technologies GmbH
“*” marked represents similar segmentation in other categories in the respective section.
Request the sample copy of here:
https://www.coherentmarketinsights.com/insight/request-sample/2514
Download the PDF Brochure here:
https://www.coherentmarketinsights.com/insight/request-pdf/2514
Buy now the market research report here:
https://www.coherentmarketinsights.com/insight/buy-now/2514
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
What we provide:
- Customized Market Research Services
- Industry Analysis Services
- Business Consulting Services
- Market Intelligence Services
- Long term Engagement Model
- Country Specific Analysis
Mr. Shah
Coherent Market Insights Pvt. Ltd.
Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.
Phone: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Source: https://www.coherentmarketinsights.com/market-insight/vagus-nerve-stimulators-market-2514